Antiinflammatory and Antiarteriosclerotic Effects of Pioglitazone

No abstract is available for this paper.

• Publication year

  2002

• Venue

  HYPERTENSION

• Publication date

  2002-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.HYP.0000036396.64769.C2PMID 12411463
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Real-Time Quantitative PCR

  2002cited by this paper
• Role of Monocyte Chemoattractant Protein-1 in Cardiovascular Remodeling Induced by Chronic Blockade of Nitric Oxide Synthesis

  2001cited by this paper
• Antiinflammatory and Antiarteriosclerotic Actions of HMG-CoA Reductase Inhibitors in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis

  2001cited by this paper
• Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

  2001cited by this paper
• Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDL

  2001cited by this paper
• Atherosclerosis The Road Ahead

  2001cited by this paper
• Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction.

  2001cited by this paper
• Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice

  2001cited by this paper
• Homocysteine stimulates the expression of monocyte chemoattractant protein-1 receptor (CCR2) in human monocytes: possible involvement of oxygen free radicals.

  2001cited by this paper
• Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration.

  2001cited by this paper
• Peroxisome proliferator-activated receptor-γ ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in Vascular smooth muscle cell migration

  2001cited by this paper
• PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

  2001cited by this paper
• Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.

  2000cited by this paper
• Redox regulation of chemokine receptor expression.

  2000cited by this paper
• Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats.

  2000cited by this paper
• Increased Activity of Nuclear Factor-κB Participates in Cardiovascular Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis in Rats

  2000cited by this paper
• Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma.

  2000cited by this paper
• Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells

  2000cited by this paper
• MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION

  2000cited by this paper
• Role of Monocyte Chemoattractant Protein-1 in Cardiovascular Remodeling Induced by Chronic Blockade of Nitric Oxide Synthesis

  2000cited by this paper
• Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

  2000cited by this paper
• Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

  2000cited by this paper
• Increased activity of nuclear factor-kappaB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats.

  2000cited by this paper
• Atherosclerosis : Vascular biology

  2000cited by this paper
• The peroxisome proliferator‐activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function

  1999cited by this paper
• Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats.

  1999cited by this paper
• Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo *

  1999cited by this paper
• Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

  1999cited by this paper
• Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma.

  1998cited by this paper
• Evidence that macrophages in atherosclerotic lesions contain angiotensin II.

  1998cited by this paper
• PPAR-γ agonists inhibit production of monocyte inflammatory cytokines

  1998cited by this paper
• Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis

  1998cited by this paper
• Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ

  1998cited by this paper
• Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.

  1998cited by this paper
• Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels.

  1998cited by this paper
• PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL

  1998cited by this paper
• PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.

  1998cited by this paper
• PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

  1998cited by this paper
• Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats.

  1998cited by this paper
• Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

  1998cited by this paper
• Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.

  1998cited by this paper
• Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats.

  1997cited by this paper
• Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis.

  1997cited by this paper
• Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

  1996cited by this paper
• Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease.

  1996cited by this paper
• Insulin Sensitivity and Atherosclerosis

  1996cited by this paper
• Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

  1996cited by this paper
• Real time quantitative PCR.

  1996cited by this paper
• Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction.

  1996cited by this paper
• Arteriosclerosis

  1925cited by this paper

• Pioglitazone attenuates cardiovascular remodeling cadmium-induced through the MAPK pathway.

  2025cites this paper
• Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat

  2024cites this paper
• Pioglitazone Protects Tubular Epithelial Cells during Kidney Fibrosis by Attenuating miRNA Dysregulation and Autophagy Dysfunction Induced by TGF-β

  2023cites this paper
• Encapsulation of Pioglitazone into Polymer-Nanoparticles for Potential Treatment of Atherosclerotic Diseases.

  2023cites this paper
• Storage Stability of Atheroglitatide, an Echogenic Liposomal Formulation of Pioglitazone Targeted to Advanced Atheroma with a Fibrin-Binding Peptide

  2023cites this paper
• Electrochemical Assays for the Determination of Antidiabetic Drugs—A Review

  2023cites this paper
• Prophylactic and Ameliorative Effects of PPAR-γ Agonist Pioglitazone in Improving Oxidative Stress, Germ Cell Apoptosis and Inflammation in Gentamycin-Induced Testicular Damage in Adult Male Albino Rats

  2022cites this paper
• Assessment of Efficacy and Safety Using PPAR-γ Agonist-Loaded Nanocarriers for Inflammatory Eye Diseases

  2022cites this paper
• Demonstration of ultrasound-mediated therapeutic delivery of fibrin-targeted pioglitazone-loaded echogenic liposomes into the arterial bed for attenuation of peri-stent restenosis

  2022cites this paper
• Atherosclerosis: Conventional intake of cardiovascular drugs versus delivery using nanotechnology - A new chance for causative therapy?

  2021cites this paper
• Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus.

  2020cites this paper
• Nanostructured Lipid Carriers of Pioglitazone Loaded Collagen/Chitosan Composite Scaffold for Diabetic Wound Healing

  2019cites this paper
• Pioglitazone Modulates the Vascular Contractility in Hypertension by Interference with ET-1 Pathway

  2019cites this paper
• Efficacy of anti‐inflammatory treatment on major depressive disorder or depressive symptoms: meta‐analysis of clinical trials

  2019cites this paper
• Therapeutic Strategies for Treatment of Inflammation-related Depression

  2017cites this paper
• Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials

  2017cites this paper
• Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.

  2016cites this paper
• Ризики лапароскопічної холецистектомії у хворих на жовчнокам’яну хворобу на тлі ішемічної хвороби серця

  2016influential citation
• Link between Metabolic Syndrome and Insulin Resistance.

  2016cites this paper
• Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT

  2016cites this paper
• Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways

  2016cites this paper
• Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition

  2015cites this paper
• Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor γ.

  2015cites this paper
• The Effects of Sub-Chronic Treatment with Pioglitazone on the Septic Mice Mortality in the Model of Cecal Ligation and Puncture: Involvement of Nitric Oxide Pathway.

  2015cites this paper
• Pioglitazone: lessons and learnings 15 years since launch and beyond

  2015cites this paper
• Pioglitazone enhances the blood pressure-lowering effect of losartan via synergistic attenuation of angiotensin II-induced vasoconstriction

  2014cites this paper
• Practical Synthesis of Pioglitazone: Ligand Substitution Reaction With Oxido Vanadium(IV) and Biological Activity

  2013cites this paper
• Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS)

  2013cites this paper
• Therapies targeting inflammation after stent implantation.

  2013cites this paper
• Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR(-/-)).

  2013cites this paper
• Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.

  2012cites this paper
• Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT1–ROS–MAPK signal pathway

  2012cites this paper
• Efficacy and safety of pioglitazone in type 2 diabetes mellitus: a postmarketing observational study.

  2012cites this paper
• Medical Lipid-Regulating Therapy

  2012cites this paper
• Pioglitazone Improves In Vitro Viability and Function of Endothelial Progenitor Cells from Individuals with Impaired Glucose Tolerance

  2012cites this paper
• Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis.

  2012cites this paper
• Pioglitazone treatment increases COX‐2‐derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function

  2012cites this paper
• Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.

  2012cites this paper
• Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats.

  2011cites this paper
• Medical therapy of aortic aneurysms: a pathophysiology-based approach.

  2011cites this paper
• Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history)

  2011cites this paper
• Dietary saturated fat/cholesterol, but not unsaturated fat or starch, induces C-reactive protein associated early atherosclerosis and ectopic fat deposition in diabetic pigs

  2011cites this paper
• Three-year clinical outcome in type 2 diabetic patients with drug-eluting stents versus bare-metal stents with pioglitazone.

  2011cites this paper
• Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension.

  2011cites this paper
• Ocular Blood Flow Analysis Detects Microvascular Abnormalities in Impaired Glucose Tolerance

  2011cites this paper
• Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine.

  2011cites this paper
• Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats.

  2010cites this paper
• From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation

  2010cites this paper
• Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.

  2010cites this paper
• Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis.

  2010cites this paper
• Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome.

  2010cites this paper
• Peroxisome proliferator-activated receptors gamma and alpha agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase.

  2010cites this paper
• Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application.

  2010cites this paper
• Chronic obstructive pulmonary disease and comorbidity: a review and consideration of pathophysiology.

  2009cites this paper
• Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.

  2009cites this paper
• Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease

  2009cites this paper
• Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice.

  2009cites this paper
• The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?

  2009cites this paper
• PPARγ agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway

  2009cites this paper
• Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone.

  2009cites this paper
• Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.

  2009cites this paper
• Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease

  2009cites this paper
• Peroxisome proliferator‐activated receptor γ (PPAR) agonism reduces the insulin‐stimulated increase in circulating interleukin‐6 in GH replaced GH‐deficient adults

  2009cites this paper
• A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes).

  2009cites this paper
• Non-alcoholic fatty liver disease and the metabolic syndrome: an update.

  2008cites this paper
• The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension.

  2008cites this paper
• Does reversal of oxidative stress and inflammation provide vascular protection?

  2008cites this paper
• Beneficial Effects of Pioglitazone on Hypertensive Cardiovascular Injury Are Enhanced by Combination With Candesartan

  2008cites this paper
• Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

  2008cites this paper
• Pioglitazone, a Thiazolidinedione Derivative, Attenuates Left Ventricular Hypertrophy and Fibrosis in Salt-Sensitive Hypertension

  2008cites this paper
• Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects.

  2008cites this paper
• Pioglitazone Enhances the Antihypertensive and Renoprotective Effects of Candesartan in Zucker Obese Rats Fed a High-Protein Diet

  2008cites this paper
• PPARγ agonist pioglitazone rescues neuronal cell damage after transient global cerebral ischemia through matrix metalloproteinase inhibition

  2008cites this paper
• Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome.

  2008cites this paper
• Inhibition of Vascular Angiotensin-Converting Enzyme by Telmisartan via the Peroxisome Proliferator–Activated Receptor γ Agonistic Property in Rats

  2007cites this paper
• PPARγ agonists—Antidiabetic drugs with a potential role in the treatment of diseases other than diabetes

  2007cites this paper
• Beneficial Effects of Pioglitazone on Left Ventricular Hypertrophy in Genetically Hypertensive Rats

  2007cites this paper
• [Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity].

  2007cites this paper
• Expression of Chemokine Receptors in Insulin-resistant Human Skeletal Muscle Cells

  2007cites this paper
• The anti-atherogenic effects of thiazolidinediones.

  2007cites this paper
• Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions.

  2007cites this paper
• The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

  2007cites this paper
• Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism

  2007cites this paper
• Importance de l’activation des PPARgamma dans la pharmacologie de la rigidité artérielle

  2007cites this paper
• Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.

  2007cites this paper
• Comparison of the Effects of Pioglitazone and Metformin on Insulin Resistance and Hormonal Markers in Patients with Impaired Glucose Tolerance and Early Diabetes

  2007cites this paper
• Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats.

  2007cites this paper
• Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy.

  2007cites this paper
• Peroxisome proliferator–activated receptor γ agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease

  2007cites this paper
• Significance of anti-inflammatory effects of PPARgamma agonists?

  2006cites this paper
• The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.

  2006cites this paper
• Insuficiencia cardíaca y diabetes

  2006cites this paper
• Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity – a common inflammatory phenotype?

  2006cites this paper
• New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).

  2006cites this paper
• Peroxisome Proliferator-Activated Receptor-γ Agonists for Management and Prevention of Vascular Disease in Patients with and without Diabetes Mellitus

  2006cites this paper
• Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy.

  2006cites this paper
• Pioglitazone and reductions in post‐challenge glucose levels in patients with type 2 diabetes

  2006cites this paper
• The effects of thiazolidinediones on blood pressure levels – A systematic review

  2006cites this paper
• Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.

  2006cites this paper
• Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.

  2006cites this paper